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A B S T R A C T
Acute Zika virus (ZIKV) infection is usually mild and self-limiting. Earlier, we reported three cases of fatal acute
ZIKV infection in patients without typical signs of ZIKV, but rather with criteria of systemic inﬂammation re-
sponse syndrome (SIRS). To follow up these observations, we prospectively included patients at the emergency
room with temperature instability and suspected to have acute ZIKV infection, SIRS, or both. A total of 102
patients were included of whom N= 21 (21%) were suspected of acute ZIKV infection, N = 56 (55%) of acute
ZIKV infection with SIRS criteria, and N = 25 (24%) of SIRS alone. ZIKV-PCR was positive in N = 21 (20%)
patients. Eight (38%) ZIKV-positive patients needed admission to the hospital of whom four (50%) presented
with SIRS alone. One ZIKV-positive patient had vascular co-morbidity and died following shock and severe
coagulopathy. We conﬁrm the hypothesis that acute ZIKV infection can present atypical and severely with
systemic inﬂammation and have lethal course particularly amongst patients with signiﬁcant prior disease.
Introduction
Zika virus (ZIKV) infection, a mosquito-borne febrile illness similar
to Dengue has spread rapidly through the Americas from 2015 into
2016 [1,2]. In Suriname, the ﬁrst cases of ZIKV were recognized in
September 2015 [3]. Most adult patients have no signs of acute ZIKV
infection. For patients with signs of ZIKV the case deﬁnition comprises a
mild and self-limiting triad of fever, maculopapular rash and poly-
arthritis. Since its arrival in the Americas, ZIKV infection is associated
with atypical Guillain-Barre syndrome in adults and with brain mal-
formations in newborns, indicating increased virulence potential [4,5].
In an earlier case series, we described three adult patients without
typical signs of acute ZIKV infection, but rather with symptoms of
systemic inﬂammation response syndrome (SIRS) and critical illness
[6]. All three patients died rapidly with ZIKV being the only micro-
biological presence, conﬁrmed by real time-polymerase chain reaction
(RT-PCR). It remains speculative if ZIKV alone, or a downwards spiral
of pre-existing disease initiated by ZIKV, was the culprit in their fatal
outcome of these cases. Several other American countries, such as Co-
lombia and Brazil, have also reported similar atypical and lethal cases
of ZIKV infection amongst adults, both with and without comorbidity or
co-infection [7–11]. These and our data indicate that acute ZIKV in-
fection can lead to critical illness and death, which was formerly un-
known [2]. Potentially, due to absence of signs of the currently ac-
cepted case deﬁnition for ZIKV, severe cases of acute ZIKV infection
have gone unnoticed during earlier outbreaks.
To investigate the severity of acute ZIKV infection, we conducted a
prospective study in the Academic Hospital in Paramaribo, Suriname.
We included adult patients at the emergency room, presenting with a
history and/or signs of ZIKV infection, SIRS criteria, or both. We hy-
pothesized that acute ZIKV infection can present with symptoms of
SIRS, often accompanied with poor outcome deﬁned as need for hos-
pitalization and death.
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Methods
Study design
Suriname is a small multiethnic country on the northeast corner of
South America with a population of approximately 550,000 in-
habitants, half of whom live in the capital city Paramaribo. The
emergency room of the Academic Hospital Paramaribo serves as the
only ER in Suriname. During a one-month period in March 2016,
trained medical students, residents and nurses performed around-the-
clock surveillance at the emergency room for inclusion of eligible pa-
tients for this prospective cross-sectional study.
We included patients above 16 years of age with a history or clinical
presentation of temperature instability (i.e., body temperature< 36 °C
or> 38 °C) with either (i) Suspected ZIKV infection, deﬁned as a his-
tory and/or clinical presentation with, at least one clinical sign of acute
ZIKV infection (i.e., maculopapular rash, myalgia, arthralgia/arthritis,
conjunctivitis), or (ii) Suspected ZIKV infection with SIRS criteria, de-
ﬁned as presentation with history and/or clinical sign of both acute
ZIKV infection with at least one SIRS criterium (i.e., a heart rate above
90 beats/min, respiratory rate above 20/min, leukocyte counts< 4
or>12 × 109/L), or (iii) SIRS, deﬁned as presentation with at least
one SIRS criterium without history and/or clinical sign of acute ZIKV
infection. Blood gas analysis was not performed routinely at inclusion
and not used as SIRS and inclusion criterium.
Upon clinical indication routine laboratory testing, serology (i.e.,
HIV, leptospirosis, and/or dengue), and bacterial culturing (i.e., blood,
urine, and/or faeces) were performed. ZIKV PCR on serum and/or urine
was performed on stored serum at the Academic Hospital Paramaribo.
Appropriate written informed consent was obtained from the study
subjects or their guardians. A copy of the written consent is available
for review by the Editor-in-Chief of this journal on request. We received
approval for this study from the Surinamese Ethical Board (VG 007-16).
Data and sample collection
The following data were recorded with a standardized ques-
tionnaire: patient age, sex, prior medical history and comorbidity
(summarized in the McCabe classiﬁcation [12]), medication including
recent antibiotics, onset of symptoms and exact current symptoma-
tology. Also recorded were physical examination, results from labora-
tory testing, serology, and culturing, and course of disease (i.e., need for
hospitalization, duration of hospital stay and/or death). Trained nurses,
students or residents collected whole blood in serum vacutainers by
vena puncture at presentation of the patients in the ER. Blood was used
for routine determination of chemical and haematological markers,
serology, and blood culturing at the Academic Hospital Paramaribo,
where indicated. Serum was separated by centrifugation at 2500 × g
for 8 min at room temperature and then residual serum was stored
immediately at −80 °C for later ZIKV PCR. Urine samples were col-
lected at the ER and used for routine urinalysis, bacterial culturing, and
stored samples for later ZIKV PCR.
Sample analysis
Real time polymerase chain reaction
ZIKV RT-PCR was performed as described before [6] by two tech-
nicians. ZIKV RNA was extracted from 150 μl of each specimen by using
the E.Z.N.A. Viral RNA Kit (OMEGA Bio-Tek), according to the manu-
facturer’s instructions. PCR was performed with SYBR Green I (Thermo
Scientiﬁc, Verso SYBR Green) for detection.
Serology
All serology was performed as described before [6]. In short, CHIKV
serology was performed with Anti Chikungunya Virus IIFT kit (Euro-
Immun) according to the manufacturer’s instructions and DENV ser-
ology was performed with RapidSignal Dengue IgG/IgM (Orgenics)
according to the manufacturer’s instructions; HIV serology was per-
formed with ELISA (Architect) and Leptospirosis serology was per-
formed with Leptochec (Zephyr Biomedicals), both according to the
manufacturer’s instructions.
Statistical analysis
Incidence rates end epidemiological determinants were calculated.
Categorical variables were presented as numbers and percentages and
continuous variables, due to the non-Gaussian distribution, as median
with interquartile range. Categorical data were compared with chi-
square and continuous variables with a Mann-Whitney U test.
Results
Baseline characteristics of the study group
A total of 102 patients were included of whom N= 21 (21%) pre-
sented with suspected ZIKV infection, N = 56 (55%) with suspected
ZIKV infection with SIRS criteria, and N = 25 (24%) with SIRS criteria
alone (Table 1). Patients with SIRS criteria were hospitalized more
(P < 0.05) and more positive blood cultures were found in the acute
ZIKV with SIRS criteria group than in the other groups (P < 0.05).
Further baseline characteristics, including positive ZIKV PCR, were si-
milar between the three groups. Of all patients, N = 43 (42%) were
admitted to the hospital. Two patients died of whom one had acute
ZIKV infection presenting with just symptoms of SIRS.
Table 1
Baseline characteristics of 102 patients at the Emergency Room in Suriname.
Patient Characteristics Suspected Zika
(N = 21)
Suspected Zika with SIRS Criteriaa
(N = 56)
SIRS Criteriaa
(N = 25)
Total Cohort (N = 102)
Baseline Characteristics Median age, y (range) 48 (19–67) 45 (17–95) 48 (17–86) 46 (17–95)
Female sex 14 (67) 34 (61) 16 (64) 64 (63)
Microbiology Positive ZIKV RT-PCR 5 (25) 11 (20) 5 (20) 21 (21)
Positive Blood Culture 1 8 (14) 1 10 (10)
Outcomes Not hospitalized 19 (90) 29 (52) 11 (44) 59 (59)
Hospitalizedb 2 (10) 27 (48) 14 (56) 43 (41)
- Median duration of stay, d
(range)
7 (4–10) 6.5 (1–16) 6.5 (3–45) 6.5 (1–45)
- 7-day mortality 0 1 1 2 (1)
SIRS = systemic inﬂammatory response syndrome; RT-PCR = real time polymerase chain reaction; ZIKV = Zika virus; NA = Not applicable.
Data presented as N (%), except as indicated.
a SIRS criteria deﬁned as a heart rate above 90 beats/min, respiratory rate above 20/min, leukocyte count< 4 or>12 × 109/L.
b Admission was either on the Internal Ward, Cardiac Care Unit, or Intensive Care Unit.
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Characteristics of ZIKV-positive patients
Of all patients, n = 81 (80%) had a negative ZIKV PCR and n = 21
(20%) a positive ZIKV PCR result, the latter being positive in either
serum (n = 17) or urine (n = 4) (Table 2). A total of 16 (76%) ZIKV-
positive patients presented with SIRS criteria, of whom N= 5 (31%)
with SIRS criteria alone. Patients with a positive ZIKV PCR presented
more often without comorbidity than the ZIKV-negative patients
(P < 0.01). Fever was less commonly reported in patients with a po-
sitive versus negative ZIKV PCR (P < 0.01). Further patient history,
physical examination, or results from laboratory testing did not dis-
criminate between negative and positive ZIKV PCR.
Severity and outcomes of acute ZIKV infection
Of 21 patients with a positive ZIKV PCR, n = 13 (62%) were not
hospitalized and discharged home directly from the ER and n = 8
(38%) were admitted to the hospital of whom one directly to the ICU
(Table 3). Of these admitted patients n = 4 (50%) presented with SIRS
criteria alone. Seven admitted patients recovered and were discharged
home. One ZIKV-positive patient presented with just symptoms of SIRS
and shock (blood pressure 60/40 mmHg), leucocytosis (16.1 × 109/L
with 90.3% granulocytes), raised CRP (29.3 mg/dL), thrombocytopenia
(125 × 109/L), and signs of coagulopathy (i.e., ecchymosis). This pa-
tient had signiﬁcant prior disease (i.e., diabetes mellitus, hypertension
Table 2
Characteristics of 102 patients at the Emergency Room in Suriname, by Zika PCR result.
Patient Characteristics<N/N> Negative Zika (N = 81) Positive Zikaa (N = 21) P-value
Baseline Characteristics Median age, y (IQR)<79/21> 46 (31–59) 46 (37–74)
Stratiﬁed Age,< 80/21>
- 18–29y 21 (26) 5 (24)
- 30–49y 20 (25) 8 (38)
- 50y or older 39 (49) 8 (38)
Female sex 51 (63) 13 (62)
Pre-existing comorbidity< 80/21>
- None 19 (24) 11 (52) < 0.01
- Hypertension 24 (30) 6 (29)
- Diabetes Mellitus 14 (18) 3 (14)
- Heart disease 0 (0) 1 (5) < 0.05
- Chronic Diseaseb 8 (10) 5 (24)
- Cancer 3 (4) 2 (10)
- Sickle Cell 3 (4) 1 (5)
- HIV 7 (9) 1 (5)
McCabe Class 1 59 (74) 10 (48) < 0.05
Patient history Median duration of symptoms, d (IQR)< 78/18> 2 (1–5) 3 (2–8) < 0.01
Fever 76 (94) 9 (43)
Arthralgia 46 (57) 9 (43)
Myalgia 45 (56) 15 (71)
Rash 8 (10) 4 (19)
Conjunctivitis 12 (15) 3 (14) < 0.05
Headache 65 (80) 12 (57)
Nausea, vomiting and/or diarrhea 59 (73) 16 (76)
Oliguria or anuria 8 (10) 5 (24)
Prior antibiotics< 79/21> 14 (18) 2 (10)
Physical Examination Fever (body temperature above 38 °C) 30 (37) 6 (30)
Median body temperature, °C (IQR) 37.8 (36.6–38.6) 37.0 (35.6–38.4)
Median Respiratory rate (IQR)< 71/17> 20 (18–24) 20 (18–23)
Median Heart rate (IQR)< 79/21> 104 (88–119) 89 (83–106) < 0.01
Median Blood pressure (sys/dia)< 80/21> 120/80 118/72
Arthritis 3 (4) 2 (10)
Rash 6 (7) 4 (19)
Edema 2 (2) 2 (10)
Petechiae and/or ecchymosis 0 1 (5)
Coma (EMV < 8) 0 0
Laboratory data, median (IQR) WBC Day 1<79/19> 9 (6–12) 10 (6–17)
PMN Day 1, %<57/14> 75 (59–81) 73 (67–90)
Platelets< 78/19> 226 (162–291) 250 (211–349)
CRP<76/19> 4 (1–14) 2 (1–7)
Albumin< 27/4> 30 (26–33) 25 (19–30)
Creatinine< 79/18> 83 (65–112) 73 (59–100)
Microbiology Positive Blood Culture< 36/6> 7 (19) 3 (50)
Leptospirosis< 10/0> 4 (40) 0 (0)
Dengue IgG antibodies< 8/1> 3 (38) 1 (100)
HIV<13/2> 2 (15) 0 (0)
Clinical Course Not hospitalized 45 (56) 13 (62)
Hospitalizedc 36 (44) 8 (38)
- Median duration of stay, d (IQR) 6.5 (4.3–12.3) 5.5 (1.8–9)
- Mortality 1 1
WBC = white blood cell count; PMN= polymorphonuclear cells; CRP = C-reactive protein; HIV = human immunodeﬁciency virus.
Data presented as N (%), except as indicated. P-values are given when signiﬁcant (P < 0.05).
a N = 17 ZIKV PCR positive results in serum and N = 4 in urine.
b Chronic disease: Migraine, anaemia, drug abuses, epilepsy, asthma, kidney disease, cerebrovascular accident or transient ischemic attack.
c Admission was either on the Internal Ward, Cardiac Care Unit, or Intensive Care Unit.
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and a coronary artery bypass grafting) and died after two days of ad-
mission to the ICU. Of the ZIKV-positive admitted patients one patient
also tested positive for Shigella.
Discussion
This prospective study was performed during the 2015–2016 ZIKV
epidemic in Suriname to investigate whether acute ZIKV infection can
present with symptoms of SIRS in addition to or instead of typical
symptoms of ZIKV infection. Amongst 102 patients, ZIKV PCR was
positive in 20% of whom 33% presented with SIRS criteria and 25%
had no history or clinical signs of acute ZIKV infection. The clinical
course of ZIKV-positive patients varied from immediate discharge from
the emergency room to requiring hospitalization and death. Overall,
this study conﬁrms that acute ZIKV infection can take an atypical, se-
vere and even lethal course, also described in earlier case reports from
our group and others [6–11].
This is the ﬁrst study that prospectively investigated severity of
acute ZIKV infection. Since the arrival of ZIKV in South America, and
the ﬁrst reports on fetal neurodegenerative eﬀects of ZIKV infection
during pregnancy and the association with atypical cases of Guillain-
Barre in adults, there has been much debate on underlying mechanisms
of increased virulence potential of ZIKV. ZIKV, identiﬁed as such in the
1950s, has been known for many years as a mild and self-limiting
disease and 70–75% of patients with ZIKV usually remain asympto-
matic [13,14]. It is, at least, puzzling that there are few, if any, reports
of severe or lethal acute ZIKV reported in earlier. Some speculations to
its increased virulent potential have been posed, such as viral factors
(e.g., genetic shift, mutation) [15], host factors (e.g., underlying disease
or circulating antibodies against DENV, a Flavivirus similar to Zika),
and environmental factors (e.g., local use of pesticides) [2,16–18]. All of
these options for severe disease remain hypothetical, even if they are in
some cases supported by in vitro and in vivo experimental data.
A ﬁnal and plausible option is that ZIKV infection has been pre-
senting severely without typical, generally acknowledged, signs of
ZIKV. In those cases, acute ZIKV infection as the cause of a patient’s
Table 3
Characteristics of 21 ZIKV positive patients, by need for hospitalization.
Not hospitalized (N = 13) Hospitalizeda (N = 8) P-value
Baseline Characteristics Median age, y (IQR) 45 (29–75) 48 (43–72)
Stratiﬁed Age
- 18–29y 4 (31) 1 (13)
- 30–49y 5 (38) 3 (38)
- 50y or older 3 (23) 4 (50)
Female sex 10 (77) 3 (38)
Pre-existing comorbidity
- None 8 (62) 3 (38)
- Hypertension 2 (15) 4 (50)
- Diabetes Mellitus 0 3 (38) < 0.05
- Heart disease 0 1 (13)
- Chronic Disease 2 (15) 3 (38)
- Cancer 2 (15) 0
- Sickle Cell 0 0
- HIV 1 (8) 1(13)
McCabe Class 1 13 (100) 8 (100)
Patient history Median duration of symptoms, d (IQR) 2 (1–3) 5 (3–14) < 0.05
Fever 10 (77) 8 (100)
Arthralgia 7 (54) 2 (25)
Myalgia 10 (77) 5 (63)
Rash 3 (23) 1 (13)
Conjunctivitis 2 (15) 1 (13)
Headache 8 (62) 6 (75)
Nausea, vomiting and/or diarrhea 8 (62) 6 (75)
Oliguria or anuria 2 (15) 3 (38)
Prior antibiotics< 13/8> 1 (8) 1 (13)
Physical Examination Fever (body temperature above 38 °C) 3 (23) 3 (38)
Median body temperature, °C (IQR) 36.8 (35.7–38.1) 37.4 (35.4–38.9)
Median Respiratory rate (IQR) 18 (16–20) 21 (18–26)
Median Heart rate (IQR) 89 (83–100) 101(80–113)
Median Blood pressure (sys/dia) 121/76 116/68
Arthritis 2 (15) 0
Rash 3 (23) 1 (13)
Edema 2 (15) 0
Petechiae and/or ecchymosis 0 1 (13)
Coma (EMV < 8) 0 0
Laboratory data, median (IQR) WBC Day 1<11/8> 8 (6–14) 15 (7–29)
PMN Day 1, %<7/7> 68 (66–75) 89 (72–90)
Platelets< 11/8> 250 (211–349) 272 (207–357)
CRP<11/8> 2 (1–3) 7 (1–29)
Albumin< 0/4> 25 (19–30)
Creatinine< 10/8> 62 (57–75) 93 (76–122)
Microbiology Positive Blood Culture<1/5> 1 2 (40)
Leptospirosis< 0/1> 0 0
Dengue IgG antibodies< 0/1> 0 1 (100)
HIV<0/2> 0 0
WBC = white blood cell count; PMN= polymorphonuclear cells; CRP = C-reactive protein; HIV = human immunodeﬁciency virus.
Data presented as N (%), except where indicated. P-values are given when signiﬁcant (P < 0.05).
a Admission was either on the Internal Ward, Cardiac Care Unit, or Intensive Care Unit.
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severe or lethal disease remains unnoticed and not likely to be con-
sidered by clinicians. Indeed, in our study half of the severe cases of
acute ZIKV infection presented without typical symptoms of ZIKV in-
fection. Proper recognition of ZIKV is further complicated by the fact
that testing for ZIKV remains diﬃcult, due to absence of sensitive ser-
ological testing and the short window during which the ZIKV PCR is
positive amongst infected individuals.
Currently, there is a lack of data on the potential of ZIKV to cause
systemic inﬂammation. Only one study has reported cytokine levels in
patients; in this study diﬀerences between acute and reconvalescent
phases of ZIKV infection were found [19]. During severe systemic in-
ﬂammation several responses are well known and consistently ob-
served, which have also been observed in the lethal cases from our
earlier case series and the fatal case observed in this study [6]. These
include increases in numbers and aberrant activation of leukocytes,
raised infection parameters, coagulopathy, oedema, hypotension,
multi-organ failure, and ultimately death [20]. Illustratively, especially
DENV is known to have the potential to cause an intravascular cytokine
storm and increased endothelial permeability without cellular damage,
both seemingly underlying systemic inﬂammation and septic shock
[21]. A similar mechanism could be involved in acute ZIKV infection.
Additionally, underlying disease may predispose to a severe course of
the disease. Indeed, all lethal cases in Suriname were male patients
above 50 years of age with prior vascular disease, hypertension and
diabetes mellitus. Interestingly, in earlier studies on DENV infection,
presence of hypertension and diabetes mellitus was associated with
transition of Dengue Fever into severe systemic inﬂammation and lethal
Dengue Hemorrhagic Fever [22]. Potentially, an entity for acute ZIKV
infection similar to Dengue Hemorrhagic Fever exists. Since ZIKV and
DENV are related viruses, both belonging to the family Flaviviridae, this
is not unlikely. Overall, from our data, there is strong indication that a
combination of both viral and host factors is likely to cause systemic
inﬂammation and critical illness in patients with acute ZIKV infection.
More prospective studies with further analysis of viral factors, such as
viral loads, and host-responses, such as measurement of intravascular
cytokines, are necessary to further unravel the potential of ZIKV to
cause systemic inﬂammation.
There is a possibility that the presence of a co-infection is co-de-
termining the severity of the clinical course of ZIKV infection. Two
patients that were hospitalized with a positive ZIKV PCR also had a
positive blood culture. One of the admitted patients in our database had
a co-infection with Shigella and appeared more ill than usual for such an
infection and needed to be admitted to the hospital. It is also known
that leptospirosis can co-exist in febrile patients with dengue and cause
exacerbated disease and that acute severe viral infections can be com-
plicated with bacterial septic shock [23,24]. Last, in vivo work in mice
indicates that presence of DENV IgG antibodies can exacerbate the se-
verity of ZIKV infection [25]. One patient in the current cohort that
needed hospitalization had IgG antibodies against DENV. Further clin-
ical evidence is needed to strengthen this hypothesis, which can be
gathered in similar studies like the current one.
The present study does have some important limitations. First, the
ZIKV epidemic in Suriname was waning in March 2016, when this study
was performed. This led to a relatively small study cohort. Second, due
to ethical constraint, we were not able to include patients not pre-
senting at the ER or without temperature instability at our ER, which
could have resulted in a selection bias. Third, due to the absence of a
serological test for Zika, we may have underestimated the true amount
of ZIKV positive patients. Last, in many ZIKV patients serology for other
infectious diseases was not performed, which may have underestimated
presence of those.
In conclusion, acute ZIKV infection can present with systemic in-
ﬂammation and severe disease. During future outbreaks, increased
vigilance for a severe and potentially lethal course of disease is war-
ranted, particularly amongst patients with signiﬁcant prior vascular
prior disease. Further research into underlying mechanisms of severe
course of acute ZIKV infection is necessary.
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